A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
May 26, 2021
End Date
February 20, 2024
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
May 26, 2021
End Date
February 20, 2024